retatrutide gip glp-1 glucagon receptor agonist Retatrutide, a GIP, and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide Phase 3: 28.7% Weight

In the LiraFlame trial, involving 102 participants with T2D, liraglutide treatment for 26 weeks led to substantial reductions in ceramides, hexocyl-ceramides, phosphatidylcholines, phosphatidylethanolamines, and triglycerides (138)

Dysbiosis, or an imbalance in gut microbiota, is associated with metabolic diseases, especially T2DM, and can cause changes in the signaling pathways of intestinal hormone secretion, leading to various health problems [156]

What Were Not Not a doctors office We dont prescribe medications or provide medical advice

I 2 = 88%, P = 0.05

I never thought I could be a 4 in pants or buy an extra small in yoga pants